Does Part D Prescription Coverage Improve Health and Reduce Inpatient Use?

D 部分处方保险是否可以改善健康并减少住院患者的使用?

基本信息

  • 批准号:
    8704846
  • 负责人:
  • 金额:
    $ 23.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our overall objective is to produce credible evidence regarding whether providing prescription drug insurance to the elderly through Medicare Part D has reduced inpatient hospitalization rates and spending and improved beneficiaries' health. To accomplish this objective we will use a novel method with considerable external and internal validity. Our method exploits data from the Medicare Current Beneficiary Survey and Health and Retirement Study to identify elderly more or less likely to gain prescription coverage through Part D. Then, using these "treatment" and "comparison" groups, we use the Medicare Provider Analysis and Review (MEDPAR) data to obtain estimates of the effect of prescription drug insurance obtained through Part D on use of, and spending on, inpatient services and mortality. We will use a sample consisting of a large portion (e.g., 70%) of all Medicare beneficiaries that will result in a study with unparalleled external validity. Estimates produced by our research will help fill a void in knowledge that is necessary to evaluate the full costs and benefits of Medicare Part D. The specific aim is to estimate associations between gaining Medicare Part D prescription drug insurance and: 1) overall rates of hospitalization and rates of hospitalization that do and do not originate in the Emergency Department; 2) hospitalization rates for specific conditions that are most plausibly linked to outpatient prescription drug use such as ambulatory care sensitive conditions; 3) annual inpatient charges (spending) and annual inpatient charges for specific types of inpatient admissions such as those for ambulatory care sensitive conditions; 4) length of stay, use of services (e.g., number of procedures) and charges associated with a hospitalization, or a hospitalization for a specific condition such as an ambulatory care sensitive condition; and 5) beneficiary mortality as measured by overall mortality and mortality following hospital admission.
描述(由申请人提供):我们的总体目标是提供可靠的证据,证明通过医疗保险D部分向老年人提供处方药保险是否降低了住院率和支出,并改善了受益人的健康。为了实现这一目标,我们将使用一种具有相当的外部和内部有效性的新方法。我们的方法利用了医疗保险当前受益人调查和健康与退休研究的数据,以确定老年人或多或少有可能通过D部分获得处方保险。然后,使用这些“治疗”和“比较”组,我们使用医疗保险提供者分析和审查(MEDPAR)数据,以获得通过D部分获得的处方药保险对住院服务和死亡率的使用和支出的影响估计。我们将使用由大部分组成的样本(例如,70%)的所有医疗保险受益人,这将导致一项研究具有无与伦比的外部效度。我们的研究得出的估计将 有助于填补评估Medicare全部成本和收益所需的知识空白 部分D.具体目的是估计获得Medicare Part D处方药保险与以下因素之间的关联:1)总体住院率以及急诊科和非急诊科的住院率; 2)与门诊处方药使用最相关的特定疾病的住院率,如门诊护理敏感性疾病; 3)年度住院费用(支出)和特定类型住院的年度住院费用,例如门诊护理敏感状况; 4)住院时间,使用服务(例如,手术次数)和与住院相关的费用,或因特定情况(如门诊护理敏感 条件;和5)受益人死亡率,以总死亡率和住院后死亡率衡量。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study.
  • DOI:
    10.1136/bmj.j4323
  • 发表时间:
    2017-10-17
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jun M;Lix LM;Durand M;Dahl M;Paterson JM;Dormuth CR;Ernst P;Yao S;Renoux C;Tamim H;Wu C;Mahmud SM;Hemmelgarn BR;Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
  • 通讯作者:
    Canadian Network for Observational Drug Effect Studies (CNODES) Investigators
Association Between Prescription Drug Insurance and Health Care Utilization Among Medicare Beneficiaries.
处方药保险与医疗保险受益人的医疗保健利用之间的关联。
  • DOI:
    10.1177/1077558716681920
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Alexander,GCaleb;Schiman,Cuiping;Kaestner,Robert
  • 通讯作者:
    Kaestner,Robert
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Kaestner其他文献

Robert Kaestner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Kaestner', 18)}}的其他基金

Legal Issues Relating to Teen Fertility
与青少年生育相关的法律问题
  • 批准号:
    9312143
  • 财政年份:
    2015
  • 资助金额:
    $ 23.67万
  • 项目类别:
Legal Issues Relating to Teen Fertility
与青少年生育相关的法律问题
  • 批准号:
    9116037
  • 财政年份:
    2015
  • 资助金额:
    $ 23.67万
  • 项目类别:
Medicaid Physician Fee and Avoidable Hospitalization
医疗补助医生费和可避免的住院治疗
  • 批准号:
    8715668
  • 财政年份:
    2013
  • 资助金额:
    $ 23.67万
  • 项目类别:
Medicaid Physician Fee and Avoidable Hospitalization
医疗补助医生费和可避免的住院治疗
  • 批准号:
    8878974
  • 财政年份:
    2013
  • 资助金额:
    $ 23.67万
  • 项目类别:
Medicaid Physician Fee and Avoidable Hospitalization
医疗补助医生费和可避免的住院治疗
  • 批准号:
    8578806
  • 财政年份:
    2013
  • 资助金额:
    $ 23.67万
  • 项目类别:
Does Part D Prescription Coverage Improve Health and Reduce Inpatient Use?
D 部分处方保险是否可以改善健康并减少住院患者的使用?
  • 批准号:
    8529439
  • 财政年份:
    2012
  • 资助金额:
    $ 23.67万
  • 项目类别:
Does Part D Prescription Coverage Improve Health and Reduce Inpatient Use?
D 部分处方保险是否可以改善健康并减少住院患者的使用?
  • 批准号:
    8341301
  • 财政年份:
    2012
  • 资助金额:
    $ 23.67万
  • 项目类别:
Youth Alcohol, Tobacco and Marijuana Use: Effects of Hours of Work and Wages
青少年吸食酒精、烟草和大麻:工作时间和工资的影响
  • 批准号:
    7579970
  • 财政年份:
    2008
  • 资助金额:
    $ 23.67万
  • 项目类别:
Youth Alcohol, Tobacco and Marijuana Use: Effects of Hours of Work and Wages
青少年吸食酒精、烟草和大麻:工作时间和工资的影响
  • 批准号:
    7465739
  • 财政年份:
    2008
  • 资助金额:
    $ 23.67万
  • 项目类别:
Welfare Reform, Fertility and Reproductive Behavior
福利改革、生育率和生殖行为
  • 批准号:
    6358692
  • 财政年份:
    2001
  • 资助金额:
    $ 23.67万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了